Replies to post #1777 on Revance Therapeutics Inc (RVNC)

[DewDiligence]

RVNC 1Q21_revenue=$13.3M—3/31/21_cash=$386.8M:

https://investors.revance.com/news-releases/news-release-details/revance-reports-first-quarter-2021-financial-results-provides

No new news on the FDA manufacturing inspection for the Daxi BLA, which has been delayed by COVID travel restrictions.

1Q21 dermal-filler sales of $11.6M were up from $10.0M in 4Q20.

1Q21 cash operating expenses of $64.2M were consistent with (actually, slightly below) RVNC’s prior guidance for full-year 2021 cash operating expenses (excluding product sales and other revenue) of $270-285M.

The 3/31/21 cash balance of $386.8M was down about $50M from 12/31/20. RVNC offset some of the 1Q21 operating cash burn by selling 0.8M shares under the ATM facility, raising $21.7M.